JPRN-UMIN000009853已完成2 期
Phase II trial of Epirubicin / Cyclophosphamide (EC) followed by Nab-paclitaxel as neoadjuvant chemotherapy for node positive breast cancer - EC followed by ABI neoadjuvant chemotherapy for node positive breast cancer (Phase II Trial)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) History of sever hypersensitivity 2) Active other malignancies 3) Severe complications (infection, uncontrolled diabetes mellitus, uncontrolled angina, heart infarction within 6 months, heart failure etc.) 4) has psychological illness which became a problem in practice 5) sever bone suppression, renal dysfunction, and liver dysfunction 6) sever pleural effusion or ascites fluid 7) has infection or fever which suspected of infection 8) pregnant or possibility of pregnant 9) Patients judged inappropriate by physicians
研究者
相似试验
招募中
不适用
Phase II randomized controlled trial of epirubicin hydrochloride and miriplatin hydrate as anticancer agents for transcatheter arterial chemoembolization of hepatocellular carcinomahepatocellular carcinomaJPRN-UMIN000011785Takasaki General Medical Center, National Hospital Organization60
进行中（未招募）
不适用
Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) + sorafenib followed by paclitaxel (P) + sorafenib in women with previously untreated primary breast cancer - SofiaWomen with previously untreated primary breast cancer.MedDRA version: 9.1Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2007-000124-41-DEGBG Forschungs GmbH36
已完成
不适用
A randomised trial of epirubicin and cyclophosphamide versus epirubicin and paclitaxel in the treatment of women with metastatic breast cancerCancerBreast cancerISRCTN75147488Medical Research Council (MRC) (UK)700
已完成
不适用
A randomized phase II trial comparing epirubicin, cisplatin, and capecitabine versus the combination of epirubicin, cisplatin, and capecitabine with pravastatin in patients with irresectable or metastatic gastric carcinomaCancerISRCTN23062732Erasmus Medical Center, Department of Medical Oncology (Netherlands)43
进行中（未招募）
1 期
A Randomised Phase II trial of Epirubicin, Oxaliplatin and Capecitebine (EOX) versus Docetaxel and Oxaliplatin (EITax) in the treatment of Advanced Gastro-oesophageal cancer - The ELECT trial - ELECT trialAdvanced Gastro-oesophageal cancerMedDRA version: 9.1Level: LLTClassification code 10062878Term: Gastrooesophageal cancerEUCTR2006-003332-29-GBICORG, all-Ireland Cooperative Oncology Research Group140